Company
Syntara Ltd
ASX:PXS
Syntara Ltd is a clinical-stage drug development company focused on the development of novel therapeutics aimed at correcting extracellular matrix (ECM) dysfunction. This will lead to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.
175 stories · page 1 of 9
Syntara advances multinational study targeting rare bone marrow cancer myelofibrosis
The clinical stage drug development company has boosted its balance sheet with a $4.4 million placement and the sale of Bronchitol Russian distribution rights for $2 million.